{"doi":"10.1002/cncr.33804","title":"Intensity‐modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial","abstract":"BACKGROUND: The use of external-beam radiotherapy for locally advanced nonanaplastic thyroid cancer remains controversial. This prospective study evaluated the efficacy and tolerability of intensity-modulated radiation therapy (IMRT) with or without concurrent chemotherapy in patients with locally advanced thyroid cancer. METHODS: The authors conducted a nonrandomized phase 2 trial of IMRT with or without concurrent doxorubicin in patients with gross residual or unresectable nonanaplastic thyroid carcinoma (ClinicalTrials.gov identifier NCT01882816). The primary end point was 2-year locoregional progression-free survival (PFS). Secondary end points included overall survival (OS), safety, patient-reported outcomes, and functional outcomes. RESULTS: Twenty-seven patients were enrolled: 12 (44.4%) with unresectable disease and 15 (55.6%) with gross residual disease. The median follow-up was 45.6 months (interquartile range, 42.0-51.6 months); the 2-year cumulative incidences of locoregional PFS and OS were 79.7% and 77.3%, respectively. The rate of grade 3 or higher acute and late toxicities was 33.4%. There were no significant functional differences 12 months after treatment (assessed objectively by the modified barium swallow study). Patient-reported quality of life in the experimental group was initially lower but returned to the baseline after 6 months and improved thereafter. In a post hoc analysis, concurrent chemotherapy with intensity-modulated radiation therapy (CC-IMRT) resulted in significantly less locoregional failure at 2 years (no failure vs 50%; P = .001), with higher rates of grade 2 or higher acute dermatitis, mucositis, and dysphagia but no difference in long-term toxicity, functionality, or patient-reported quality of life. CONCLUSIONS: In light of the excellent locoregional control rates achieved with CC-IMRT and its acceptable toxicity profile as confirmed by functional assessments and patient-reported outcomes, CC-IMRT may be preferred over IMRT alone.","journal":"Cancer","year":2021,"id":171005,"datarank":0.8627648944579677,"base_score":3.332204510175204,"endowment":3.332204510175204,"self_citation_contribution":0.49983067652628066,"citation_network_contribution":0.362934217931687,"self_endowment_contribution":0.49983067652628066,"citer_contribution":0.362934217931687,"corpus_percentile":null,"corpus_rank":null,"citation_count":27,"citer_count":27,"citers_with_citation_signal":16,"citers_with_endowment":16,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9602,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT01882816"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":255786,"name":"Eric J. Sherman","orcid":"0000-0002-4960-4783","position":1,"is_corresponding":false},{"id":704740,"name":"Karissa Whiting","orcid":"0000-0002-4683-1868","position":2,"is_corresponding":false},{"id":705607,"name":"Margaret L. Ho","orcid":null,"position":3,"is_corresponding":false},{"id":519310,"name":"Ashok R. Shaha","orcid":"0000-0001-7478-9436","position":4,"is_corresponding":false},{"id":564662,"name":"Mona M. Sabra","orcid":"0000-0001-8686-2258","position":5,"is_corresponding":false},{"id":236122,"name":"Nadeem Riaz","orcid":"0000-0001-9873-5862","position":6,"is_corresponding":false},{"id":704741,"name":"T. Waldenberg","orcid":"0000-0002-1933-6925","position":7,"is_corresponding":false},{"id":705608,"name":"C. Sabol","orcid":null,"position":8,"is_corresponding":false},{"id":267983,"name":"Ian Ganly","orcid":"0000-0001-7636-5426","position":9,"is_corresponding":false},{"id":255799,"name":"Sean M. McBride","orcid":"0000-0002-9676-1669","position":10,"is_corresponding":false},{"id":108810,"name":"James A. Fagin","orcid":"0000-0002-2365-2517","position":11,"is_corresponding":false},{"id":281409,"name":"Zhigang Zhang","orcid":"0000-0002-1556-7945","position":12,"is_corresponding":false},{"id":55870,"name":"R. Michael Tuttle","orcid":"0000-0001-9899-9702","position":13,"is_corresponding":false},{"id":255806,"name":"Richard J. Wong","orcid":"0000-0001-6259-7314","position":14,"is_corresponding":false},{"id":255810,"name":"Nancy Y. Lee","orcid":"0000-0003-3044-9522","position":15,"is_corresponding":false},{"id":228776,"name":"Paul B. Romesser","orcid":"0000-0001-8268-2903","position":0,"is_corresponding":true}],"reference_count":24,"raw_metadata":null,"created_at":"2026-07-18T23:46:28.747384Z","pmid":"34293201","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}